Several claims in Eli Lilly & Co.’s patent on its Cialis erectile dysfunction drug are obvious in light of earlier research involving the same drug in higher dosages, a U.K. appeals court ruled Nov. 1.
The decision is a victory for Teva UK Ltd. and Mylan’s UK division, Generics (UK) Ltd., as they prepare generic versions of the drug. Cialis generated $2.46 billion in worldwide sales in 2016, according to Eli Lilly.
Earlier research discussed using tadalafil, the generic name for Cialis, in a 50 milligram dose for inhibiting a chemical relating to erectile dysfunction. It would have been obvious ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.